Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Change in Accured Expenses (2016 - 2025)

Standard Biotools (LAB) has disclosed Change in Accured Expenses for 16 consecutive years, with $10.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 2567.32% to $10.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 37.28% decrease, with the full-year FY2024 number at -$4.2 million, down 167.67% from a year prior.
  • Change in Accured Expenses was $10.1 million for Q3 2025 at Standard Biotools, up from $40000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $10.1 million in Q3 2025 to a low of -$7.6 million in Q4 2024.
  • A 5-year average of $293421.1 and a median of $40000.0 in 2025 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 1390.6% in 2021, then soared 2567.32% in 2025.
  • Standard Biotools' Change in Accured Expenses stood at -$5.4 million in 2021, then skyrocketed by 283.19% to $9.9 million in 2022, then plummeted by 92.57% to $735000.0 in 2023, then crashed by 1138.64% to -$7.6 million in 2024, then surged by 232.51% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Change in Accured Expenses are $10.1 million (Q3 2025), $40000.0 (Q2 2025), and $103000.0 (Q1 2025).